

Meningococcal (A,C,W,Y) Vaccine

Vaccine Description	<ul style="list-style-type: none"> • Brands: Menveo® and MenQuadfi® • Inactivated, bacterial polysaccharide conjugate (MCV4) • See package insert 	
Dose & Route	<ul style="list-style-type: none"> • Dose: 0.5 mL • Route: IM (Menveo®, MenQuadfi®) (Precaution: hemophilia, thrombocytopenia, and anticoagulation therapy) • See package insert 	
Indications	<ul style="list-style-type: none"> • Routine vaccination against meningococcal disease is not recommended for children aged 2 months through 10 years of age. • All children at age 11 to 12 years and unvaccinated adolescents at subsequent visit • College freshmen living in dormitories • Children 2 months and older who: <ul style="list-style-type: none"> • Have functional or anatomic asplenia, including sickle cell disease • Have certain immune system disorders (complement component deficiency) • Are traveling to or living in an endemic area • Have been exposed to meningitis during an outbreak • Have HIV • Are taking a complement inhibitor (e.g., Solaris) • Menveo® is licensed for use in ages 2 months - 55 years of age; MenQuadfi® is licensed for ages 2 years and older 	
Administration Schedule	Age	Schedule
	INCREASED RISK 2-23 mos of age (complement deficiency; asplenia; outbreak; HIV; travel)	Primary vaccination: Menveo: If first dose at age: <ul style="list-style-type: none"> • 2 mos: 4 doses at 2, 4, 6, and 12 mos • 3-6 mos: 8-week intervals until ≥ 7 months. One additional dose is given ≥7 months followed by 1 dose at least 12 weeks later and after the 1st birthday • 7-23 mos: 2 doses (second dose ≥12 wks after the first dose and after the 1st birthday)
	NO RISK 11-18 yrs of age	Give dose #1 of 2-dose MCV4 series. Dose #2 will be due at age 16 years. For 1st yr college student (19 - 21 yrs in dorm): 1 dose MCV4 if none prior, or 1 dose (#2) if single dose given before age 16.
See package insert for vaccine-specific schedule		

Continued on Next Page

Meningococcal (A,C,W,Y) Vaccine (Continued)

Administration Schedule (continued) See package insert for vaccine-specific schedule	TRAVEL RISK 2-18 yrs of age (Travel to endemic area or outbreak)	If unimmunized: 1 dose of MCV4 with booster every 5 years if travel risk persists
	HEALTH RISK 2-18 yrs of age (complement deficiency; asplenia, HIV)	Primary: Menveo or MenQuadfi <ul style="list-style-type: none"> • 2 doses ≥8 wks apart • Boosters (if person remains at increased risk) • Aged <7 yrs: Single dose at 3 yrs after primary vaccination and every 5 yrs thereafter • Aged ≥7 yrs: Single dose at 5 yrs after primary vaccination and every 5 yrs thereafter
Contraindications	<ul style="list-style-type: none"> • Serious allergic reaction to prior dose or vaccine component • Moderate or severe acute illness • Children younger than 2 months of age (Menveo®) or 2 years of age (MenQuadfi®) • Menveo: severe allergic reaction to any diphtheria toxoid or CRM197 containing vaccine • MenQuadfi: severe allergic reaction to a tetanus toxoid-containing vaccine 	
Special Considerations	<ul style="list-style-type: none"> • Menveo® and MenQuadfi® have not been widely studied in pregnant and lactating women and should be given only if clearly indicated. • **Penbraya (MenABCWY) is licensed as a 2-dose series given 6 months apart, for individuals aged 10-25 years. Pfizer's MenABCWY vaccine may be used when both MenACWY and MenB are indicated at the same visit for: <ul style="list-style-type: none"> ◦ Healthy individuals age 16 through 23 years (routine schedule) when shared clinical decision-making (SCDM) favors administration of MenB vaccination (requires order from privileged provider). ◦ Individuals age 10 years and older at increased risk of meningococcal disease (e.g., due to persistent complement deficiencies, complement inhibitor use, or functional or anatomic asplenia) due for both vaccines ◦ The MenB component of Penbraya is the MenB vaccine Trumenba. As Trumenba and Bexsero are not interchangeable, a primary series and any future MenB booster doses must be of the same brand. • See Storage and Handling Section 	
<p>VIS: http://www.cdc.gov/vaccines/hcp/vis/vis-statements/mening.html Standing orders: www.health.mil/standingorders Dosing Schedule: www.immunize.org/catg.d/p2018.pdf Pregnancy registry for Menactra®: 1-800-822-2463 Pregnancy registry for Menveo®: 1-877-413-4759; also notify DHA-IHD Additional education may be found at www.health.mil/meningococcal</p>		